Medtronic plc (MDT)
Medtronic plc is a global leader in medical technology, specializing in medical devices, therapies, and solutions for various chronic diseases. Founded in 1949 and headquartered in Ireland, the company develops products for areas such as cardiac and vascular care, diabetes management, neurological disorders, and surgical equipment, aiming to improve patient outcomes and healthcare efficiency worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 17, 2025 | $0.71 | 2025-09-26 | 2025-09-26 |
| July 11, 2025 | $0.71 | 2025-06-27 | 2025-06-27 |
| April 11, 2025 | $0.70 | 2025-03-28 | 2025-03-28 |
| January 10, 2025 | $0.70 | 2024-12-27 | 2024-12-27 |
| October 11, 2024 | $0.70 | 2024-09-27 | 2024-09-27 |
Dividends Summary
- Medtronic plc has issued 87 dividend payments over the past 21 years
- The most recent dividend was paid 35 days ago, on October 17, 2025
- The highest dividend payed out to investors during this period was $0.71 per share
- The average dividend paid during this period was $0.37 per share.
Company News
The global internal neuromodulation devices market is projected to grow from $11.81 billion in 2024 to $44.57 billion by 2033, driven by AI-powered personalized therapies, miniaturization, and increasing demand for non-opioid pain management solutions.
Medtronic's stock is showing positive momentum after a strong Q2 performance, with potential for 20-30% price appreciation driven by mid-single-digit growth, healthy margins, and consistent capital returns.
Bank of America maintains a Buy rating for Medtronic, expecting over 5% revenue growth in fiscal Q2 and strong momentum through 2026, with potential expansion in cardiac ablation solutions and renal denervation.
Intuitive Surgical reported strong Q3 earnings with 23% sales growth, beating analyst expectations. The company's robotic surgery systems saw significant demand, with a 33% increase in system sales and expanded profit margins.
Medtronic's (MDT) stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.
